

---

## OBSTETRICS

---

# Prevalence of Gestational Diabetes Mellitus Detected by International Association of the Diabetes and Pregnancy Study Groups (IADPSG) Criteria in Phramongkutkla Hospital

Rathawit Suntorn, MD\*,  
Prisana Panichkul, MD\*.

\* Department of Obstetrics & Gynecology, Phramongkutkla Hospital, Bangkok 10400, Thailand

## ABSTRACT

**Objective:** To determine the prevalence of gestational diabetes mellitus (GDM) diagnosed with International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria and identify risk factors of GDM in pregnant women who attended antenatal clinic at Phramongkutkla Hospital.

**Materials and Methods:** This was a descriptive study. Pregnant women who underwent antenatal visit at Phramongkutkla Hospital from December 2013 to September 2014 were enrolled and universal screening for GDM was done. After exclude multi-fetal pregnancy and overt DM, the remaining subjects were reviewed for age, gravida, parity, gestational age at screening, expected date of confinement (EDC), known risk factors of GDM, past and personal histories. A 2-hours 75 gm oral glucose tolerance test (75-gm OGTT) was performed. Outcome was the prevalence of pregnant women with GDM and risk factor for GDM among selected population.

**Results:** Three hundred and twenty-five pregnant women were included. Mean age was 29.72 years old. One hundred and eight women was in high risk group (33.23%), 193 (59.38%) and 24 (7.39%) women were identified in average and low risk group, respectively. The prevalence of GDM was 21.8%, which is comparable to reported range from previous studies. Risk factors associated with GDM was age  $\geq$  35 years.

**Conclusion:** The prevalence of pregnant women with GDM in antenatal clinic at Phramongkutkla Hospital diagnosed with IADPSG criteria was 21.8% and the risk factor for GDM was age  $\geq$  35 years.

**Keywords:** gestational diabetes mellitus, IADPSG, 2-hours 75 gm OGTT

## Introduction

Gestational diabetes mellitus (GDM) is one of the most common medical problems in pregnancy<sup>(1)</sup>. Of all the pregnant women complicated with diabetes

mellitus (DM), 90 % of which were GDM while the rest were pre-gestational DM that was first recognized during pregnancy<sup>(2)</sup>. The prevalence of GDM was reported to be 6-7 % various among ethnicity and

prevalence of type 2 DM in each population<sup>(1)</sup>. Undetected or poor controlled GDM can lead to adverse pregnancy outcomes for both mother and fetus<sup>(3-4)</sup>. Early diagnosis and appropriate treatment to control blood sugar can help to prevent these adverse consequences<sup>(5)</sup>.

Screening and diagnostic test for GDM had long been interested and evaluated in many studies. O'Sullivan and Mahan<sup>(6)</sup> (1964) first published a criteria for oral glucose tolerance test (OGTT) in pregnancy which was followed by a screening criteria for high-risk gestational diabetic patients<sup>(7)</sup>. The National Diabetes Data Group<sup>(8)</sup> (NDDG), Carpenter and Coustan<sup>(9)</sup>, and the American Diabetes Association<sup>(10)</sup> (ADA) subsequently recommended different cut-off criteria for diagnosis of GDM which were widely used in many countries. In 2005, the fifth international workshop conference on GDM<sup>(11)</sup> proposed risk-stratified management in screening of GDM into three groups: low risk - no need for screening, moderate risk - screening at 24-28 weeks of gestation, and high risk - screening at first antenatal visit and repeat at 24-28 weeks of gestation. They also suggested that either one-step approach with 75-gm OGTT or two-step approach with 50-gm glucose challenge test (50-gm GCT) followed by 100-gm OGTT was appropriate in GDM screening<sup>(11)</sup>. Recently, the International Association of Diabetes and Pregnancy Study Group<sup>(12)</sup> (IADPSG), based on data from the hyperglycemia and adverse pregnancy outcome research cooperative study group<sup>(13)</sup> (HAPO study) which focused on pregnancy outcome in pregnant women, found that the criteria for diagnosis of GDM would be more correlated with fetal macrosomia and caesarean delivery rate when thresholds of a 2-hour 75-gm OGTT was set to be  $\geq 92$ ,  $\geq 180$  and  $\geq 153$  mg/dl for fasting plasma glucose, 1-hr plasma glucose and 2-hr plasma glucose, respectively. GDM was diagnosed when at least one abnormal value was found.

Traditionally at Phramongkutkla Hospital, two-step approach was performed after pregnant women were classified by their risk factors. One-hour 50-gm GCT will be tested first. If the value was  $\geq 140$  mg/dl, which was defined as abnormal, then a 3-hour 100-gm

OGTT will subsequently be performed. Thus, the data regarding prevalence of GDM after diagnosed with one-step approach by 2-hour 75-gm OGTT (IADPSG) in Phramongkutkla Hospital will have never been published before. Also, 2-hr 75-gm OGTT was superior to two-step approach because it requires shorter time to completion, decrease health care cost and increase patient satisfactory. So, the objectives of this study were proposed to determine the prevalence of GDM diagnosed by IADPSG criteria in Phramongkutkla Hospital and the risk associated with GDM in selected population.

## Materials and Methods

This was a descriptive study conducted at Phramongkutkla Hospital after approval by the Institutional Review Board, Royal Thai Army, Medical Department. Pregnant women who seek for antenatal care (ANC) at Phramongkutkla Hospital from December 2013 to September 2014 were informed and enrolled for universal screening for GDM with a 2-hour 75-gm OGTT at gestational age (GA) of 24 – 28 weeks. The test was scheduled for each patient and done at antenatal clinic following standard methods recommended by IADPSG<sup>(13)</sup>. Blood specimens were analyzed for plasma glucose in the laboratory of Phramongkutkla Hospital by using Cobas 6000 analyzer, Roche/Hitachi, Thailand. After exclude multi-fetal pregnancy and overt DM diagnosed by taking medical history or FPG from the test of  $\geq 126$  mg/dl, the remaining subjects were reviewed for age, gravida, parity, GA at first ANC, GA at screening, past and personal histories associated with DM, known risk factors of GDM including age  $\geq 35$  years, pre-gestational BMI  $\geq 30$  kg/m<sup>2</sup>, previous history of GDM, history of DM in 1<sup>st</sup> degree relatives, previous unexplained fetal death or stillbirth, previous infant birth weight  $\geq 4,000$  g, and glucosuria or history of impaired glucose metabolism. Women with any of these risk factors were classified as high risk group. Average risk group was women aged 25-34 years. Women who had no mentioned risk were identified as low risk group. Primary outcome was the prevalence of GDM diagnosed by 2-hour 75-gm OGTT (IADPSG criteria). Secondary outcome was the

risk factors for GDM between normal and GDM women.

### Statistical analysis

Based on a prevalence of GDM at 23% in HAPO study<sup>(14)</sup>, a total of 355 participants were needed in this study. Data were analyzed using IBM SPSS statistic 19.0. Characteristics data of population will be presented with number, percentage, average, standard deviation. Continuous data were compared using t-test or Mann-Whitney U test, while categorical data were compared using chi-square or Fisher's exact test. P< 0.05 was considered statistical significant difference.

## Results

**Table 1.** Demographic data of the population.

	<b>N = 325</b>	<b>%</b>
<b>Age* (year)</b>	<b>29.72 ± 4.76</b>	
< 25	49	15.08
25 - 29	108	33.23
30 - 34	120	36.92
> 35	48	14.77
<b>Gravida</b>		
1	129	39.69
2	127	39.07
≥ 3	69	21.24
<b>Parity</b>		
0	156	48.00
1	119	36.62
≥ 2	50	15.38
<b>GA at First ANC* (weeks)</b>	<b>12.07 ± 4.36</b>	
<b>Corrected GA by:</b>		
- LMP	292	89.84
- Ultrasound	33	10.16
<b>GA at screening<sup>†</sup> (weeks)</b>	<b>25.61 (24-28)</b>	

\* Presented by Mean ± SD

† Presented by Median (range)

Of all women who went to ANC clinic at Phramongkutkla Hospital in the study period, 397 women were interested and provided informed consent for the study. Three hundred and twenty-five pregnant women were finally recruited while 54 patients were excluded due to loss follow up (38), abortion (9), twin pregnancy (1), overt DM after test (1) and change their mind (6). Table 1 shows the demographic data of the population. Mean age was 29.72 years. Primigravida comprised almost 40% of cases. All patients underwent screening at accurate GA (24-28 weeks). Demographic data between normal and GDM cases were compared in Table 2. Prevalence of GDM diagnosed by IADPSG criteria was 21.8% (N=71).

**Table 2.** Comparison of demographic data between non-GDM and GDM women.

	Non-GDM (N=254)	GDM (N=71)	P*
	N (%)	N (%)	
Age (year)	29.21 ± 4.52	31.54 ± 5.26	0.001*
<b>Gravida</b>			
1	106 (41.89)	23 (32.3)	
2	94 (36.94)	33 (46.48)	0.206†
≥ 3	54 (21.17)	15 (21.12)	
<b>Parity</b>			
0	130 (51.18)	26 (36.62)	
1	86 (33.86)	33 (46.48)	0.59†
≥ 2	38 (14.96)	12 (16.90)	
GA at First ANC (weeks)	12.27 ± 4.41	11.39 ± 4.12	0.156*
GA at screening (weeks)	25.61 (24-28)	25.63 (24-28)	0.924‡
<b>Plasma glucose (mean ± SD)</b>			
FPG	80.72 ± 5.94	89.17 ± 9.40	< 0.001*
1-hr PG	134.74 ± 25.86	181.17 ± 26.20	< 0.001*
2-hr PG	106.17 ± 20.48	134.58 ± 30.38	< 0.001*
<b>Abnormal plasma glucose</b>			
Abnormal FPG	0	29 (40.85)	
Abnormal 1-hr PG	0	40 (56.34)	NA
Abnormal 2-hr PG	0	23 (32.39)	
<b>Risk group</b>			
Low risk	24 (9.46)	0	
Average risk	156 (61.26)	37 (52.11)	0.002†
High risk	74 (29.28)	34 (47.89)	

\* t-test

‡ Mann-Whitney U test

† Chi-square test

NA = not available

There was no statistical significant difference when compared demographic data between two groups ( $p > 0.05$ ) except for age ( $p = 0.001$ ), which is one of known risk factors for GDM. However the mean ages in both groups were still lower than cut point risk for GDM (< 35 years) (Table 2). No pregnant women who established abnormal test was identified in low risk group and risk stratification was also significant different between non-GDM and GDM groups ( $p = 0.002$ ).

Known risk factors of GDM were compared and showed in Table 3. Only age  $\geq 35$  years showed significant difference ( $p = 0.008$ ). Most other risk factors present in few cases; BMI  $\geq 30$  kg/m $^2$ , previous unexplained fetal death/stillbirth, previous infant birth weight  $\geq 4,000$  g. Some factors were found only in one group; previous GDM, hypertension. Some factors were not even present; impaired glucose metabolism.

**Table 3.** Comparison of GDM Risk factors between non-GDM and GDM women.

	Non-GDM (N = 254)	GDM (N = 71)	P*
	N (%)	N (%)	
Age (year)	29.21 ± 4.52	31.54 ± 5.26	0.001*
BMI ≥ 30 kg/m <sup>2</sup>	1 (0.39)	2 (2.82)	0.127†
Age ≥ 35 years	30 (11.81)	18 (25.35)	0.008*
Previous GDM	1 (0.39)	0	1.000†
DM in 1st degree relatives	37 (14.57)	14 (19.72)	0.254*
Previous unexplained fetal death/stillbirth	1 (0.39)	2 (2.82)	0.127†
Previous infant birth weight ≥ 4,000 g	1 (0.39)	1 (1.41)	0.398†
Glucosuria	6 (2.36)	4 (5.63)	0.117†
Impaired glucose metabolism	0	0	0
Hypertension	0	2 (2.82)	1.000†

\* Chi-Square test

† Fisher's exact test

## Discussion

Our study revealed the prevalence GDM among participated pregnant women at antenatal clinic at Phramongkutkla Hospital was 21.8% after universally screening was done by using IADPSG criteria, which was similar to the prevalence of GDM formerly reported by Rajavithi Hospital (23%)<sup>(14)</sup>. It was also comparable to the prevalence found from HAPO study<sup>(14)</sup> – 17.8% (9.3 - 25.5%) - which studied among 15 centers around the world using the same criteria. Some studies reported lower prevalence for GDM<sup>(5,15)</sup>, such as, Kanthiya and colleagues<sup>(5)</sup> found the prevalence in Bhumibol Adulyadej Hospital, at 2.6%. The difference in GDM prevalence from the study of Kanthiya and colleagues<sup>(5)</sup> possibly due to their exclusion of those women (5,675 from 6,324) who identified as no risk factors (age < 30, had no fetal anomaly associated hyperglycemia, and had no clinical of impaired glucose) from the screening program. While in our study, we also included all women regardless of age.

From the demographic data (Table 1), we found that the risk-based group was significant different ( $p < 0.05$ ) between non-GDM and GDM women. We suggested that risk stratification was benefit in screening program because there was no GDM in low risk group, thus the test might not be offered in these women.

When compared in detailed for each risk factor, age was the only risk factor that associated with GDM. Although, other risk factors showed unremarkable p-value, this interpretation was limited due to number of cases for each risk factor was too low and some were not present in both compared groups. One previous GDM case was found only in non-GDM group but not found in GDM group, while hypertension case were identified only in GDM group. Only few cases had previous unexplained fetal death/stillbirth or previous infant birth. History of impaired glucose was not found in either group. We decided not to further analyze by using regression analysis.

Apart from diagnosis criteria and risk factor identification, adverse pregnancy consequences were interested in many recent studies<sup>(5, 16-18)</sup>. IADPSG criteria will rise prevalence of GDM 3-4 times compared with traditional criteria<sup>(16-19)</sup> (from 7-8%<sup>(20)</sup> to 21.8% in our study) while pregnancy outcome showed inconclusive results among studies. In the study of Kanthiya, et al<sup>(5)</sup>, found that some adverse maternal and neonatal outcomes were showed when women diagnosed by IADPSG criteria compared with normal women including pregnancy induced hypertension, rate of primary cesarean section, low APGAR score at 5 minutes, neonatal hypoglycemia and NCIU admission

rate. Contrary, Bodmer-Roy, et al<sup>(16)</sup>, found no statistical significant difference in adverse pregnancy outcome of women diagnosed by IADPSG criteria compared with Canadian Diabetes Association criteria<sup>(16)</sup>. In our study, we did not follow up all pregnant women until the time of delivery for pregnancy outcomes. However, we were agreed with Bodmer-Roy that a cost-effectiveness study should be performed before applying IADPSG criteria universally<sup>(16)</sup>.

According to this study, the number of sample size was calculated for determine the prevalence of GDM detected by IADPSG criteria and may be too low to identify the GDM risk factors. As mentioned, some risk factors were even not found in our study due to prevalence among selected population that recruited in this study was limited.

## Conclusion

The prevalence of GDM detected by IADPSG criteria in Phramongkutkla Hospital was 21.8% (N = 71) and the risk factor for GDM was age  $\geq$  35 years.

## References

1. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics: ACOG Practice Bulletin. Clinical management guidelines for obstetrician- gynecologists. Number 137, August 2013 (replaces Technical Bulletin Number 30, September 2001). Gestational diabetes mellitus. *Obstet Gynecol* 2013;122:406-16.
2. Wier LM, Witt E, Burgess J, Elixhauser A. Hospitalizations related to Diabetes in Pregnancy, 2008. HCUP Statistical Brief #102. Rockville (MD): Agency for Healthcare Research and Quality; 2010.
3. Yoge Y, Xenakis EM, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. *Am J Obstet Gynecol* 2004;191:1655-60.
4. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes care* 2010; 33:676-82.
5. Kanthiya K, Luangdansakul W, Wacharasint P, Prommas S, Smanchat B. Prevalence of Gestational Diabetes Mellitus and Pregnancy Outcomes in Women with Risk Factors Diagnosed by IADPSG Criteria at Bhumibol Adulyadej Hospital. *Thai J Obstet Gynaecol* 2013; 21:141-9.
6. O'Sullivan JB, Mahan CM. Criteria for oral glucose tolerance test in pregnancy. *Diabetes* 1964; 13:278-85.
7. O'Sullivan JB, Mahan CM, Charles D, Dandrow RV. Screening criteria for high-risk gestational diabetic patients. *Am J Obstet Gynecol* 1973;116:895-900.
8. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979;28:1039-57.
9. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol* 1982; 144:768-73.
10. American Diabetes Association. Gestational Diabetes Mellitus. *Diabetes Care* 2000;23:S77-9.
11. Metzger BE, Buchanan TA, Coustan DR, Leiva AD, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on gestational diabetes mellitus. *Diabetes Care* 2007;30:S251-9.
12. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycaemia in pregnancy. *Diabetes Care* 2010; 33:676-82.
13. The HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcomes. *N Engl J Med* 2008;358:1991-2002.
14. Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria. *Diabetes Care* 2012;35:526-28.
15. Priyanka K, Chetan PK, Hilda VS. Prevalence of gestational diabetes mellitus and its outcome in western Rajasthan. *Indian J Endocrinol metab* 2013;17:677-80.
16. Bodmer-Roy S, Morin L, Cousineau J, Rey E. Pregnancy Outcomes in Women With and Without Gestational Diabetes Mellitus According to The International Association of the Diabetes and Pregnancy Study Groups Criteria. *Obstet Gynecol* 2012;120:746-52.
17. Lapolla A, Dalfra MG, Ragazzi E, De Cata AP, Fedele D. New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnancy outcome. *Diabet Med* 2011;28:1074-7.
18. O'Sullivan EP, Avalos G, O'Reilly M, Dennedy MC, Gaffney G, Dunne F. Atlantic Diabetes in Pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. *Diabetologia* 2011;54:1670-5.
19. Jenum AK, Mørkrid K, Sletner L, Vange S, Torper JL, Nakstad B, et al. Impact of ethnicity on gestational diabetes identified with the WHO and the modified International Association of Diabetes and Pregnancy Study Groups criteria: a population-based cohort study. *Eur J Endocrinol* 2012;166:317-24.
20. Obstetric Statistics, Department of Obstetrics and Gynecology, Phramongkutkla Hospital 2008-2010.

---

## ความซุกของการเกิดเบาหวานขณะตั้งครรภ์ โดยใช้เกณฑ์ของ International Association of the Diabetes and Pregnancy Study Groups (IADPSG) ในโรงพยาบาลพระมงกุฎเกล้า

รัชวิชญ์ สุนทร, ปริศนา พานิชกุล

**วัตถุประสงค์ :** เพื่อหาความซุกของการเกิดเบาหวานขณะตั้งครรภ์ที่เป็นเบาหวานขณะตั้งครรภ์ตามเกณฑ์การวินิจฉัยของ IADPSG และปัจจัยเสี่ยงต่อการเกิดเบาหวานขณะตั้งครรภ์ในสตรีที่มาฝากครรภ์ที่โรงพยาบาลพระมงกุฎเกล้า

**วัสดุและวิธีการ :** ทำการศึกษาระหว่างเดือนธันวาคม พ.ศ. 2556 ถึงเดือนกันยายน พ.ศ. 2557 ในสตรีตั้งครรภ์เดียวที่ฝากครรภ์ก่อน อายุครรภ์ 28 สัปดาห์ทุกราย และไม่รวมสตรีตั้งครรภ์แพดหรือสตรีที่ทราบว่าเป็นเบาหวานมาก่อนตั้งครรภ์ในการศึกษา โดยบันทึกข้อมูล อายุ จำนวนการตั้งครรภ์ อายุครรภ์ที่ตรวจด้วยกล้อง กำหนดคลอด ปัจจัยเสี่ยงของการเกิดเบาหวานขณะตั้งครรภ์ ประวัติในอดีต และ ประวัติส่วนตัว ซึ่งการตรวจจะใช้วิธี 75-gm OGTT เพื่อให้ได้ค่าความซุกของการเกิดเบาหวานขณะตั้งครรภ์

**ผลการศึกษา :** สตรีตั้งครรภ์จำนวน 325 รายที่เข้าร่วมการศึกษา มีอายุเฉลี่ย 29.72 ปี ซึ่งเป็นกลุ่มที่มีความเสี่ยงสูงต่อการเป็น เบาหวานขณะตั้งครรภ์ 108 ราย (ร้อยละ 33.23) ความเสี่ยงปานกลาง 193 ราย (ร้อยละ 59.38) และความเสี่ยงต่ำ 24 ราย (ร้อยละ 7.39) โดยมีความซุกของการเกิดเบาหวานขณะตั้งครรภ์ร้อยละ 21.8 ซึ่งใกล้เคียงกับการศึกษาที่เคยมีมาก่อน ปัจจัยเสี่ยงที่มีผลต่อการ เกิดเบาหวานขณะตั้งครรภ์คือ อายุ 35 ปีขึ้นไป

**สรุป :** ความซุกของการเกิดเบาหวานขณะตั้งครรภ์โดยใช้เกณฑ์ของ (IADPSG) ในโรงพยาบาลพระมงกุฎเกล้าเท่ากับร้อยละ 21.8 และ ปัจจัยเสี่ยงของการเกิดเบาหวานขณะตั้งครรภ์คือหูงิ้งตั้งครรภ์ที่มีอายุตั้งแต่ 35 ปี ขึ้นไป

---